Cover Image
市場調查報告書

全球流感市場:疫苗、治療藥

Global Influenza Market - Vaccines and Therapeutics

出版商 Industry Experts 商品編碼 355501
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
Back to Top
全球流感市場:疫苗、治療藥 Global Influenza Market - Vaccines and Therapeutics
出版日期: 2016年03月30日 內容資訊: 英文 128 Pages
簡介

全球流感疫苗、治療藥市場規模,預計從2016到2022年以8.5%的年複合成長率發展,從2016年的61億美元到2022年達到102億美元。疫苗市場區隔構成著流感市場約80%,不過,預計治療藥市場區隔在預測期間內以最高11%的年複合成長率成長。

本報告提供全球流感疫苗、治療藥市場相關調查分析,市場概要,開發平台的主要產品,市場趨勢,產業趨勢,各地區的市場展望,及主要企業的簡介等彙整。

A部分:全球市場的展望

第1章 簡介

第2章 開發平台的主要產品

  • 開發平台的流感疫苗
  • 開發平台的流感治療

第3章 主要市場趨勢

  • 研究引導新抗流感藥的開發
  • 減少流感相關的心房纖維顫動的可能性由流感疫苗表明
  • 為了與流感作戰的設計者藥物
  • 基於細胞培養的流感疫苗的氣勢漸增
  • 流感疫苗生產的新興技術
  • 傳統的季節性流感疫苗為植物來源疫苗
  • 目標鎖定流感的創新藥物的開發中HHS市場的進步

第4章 主要企業

  • Abbott Laboratories
  • Astrazeneca PLC
  • Biocryst Pharmaceuticals, Inc.
  • CSL Limited
  • 第一三共
  • Glaxosmithkline PLC
  • Hualan Biological Engineering Inc.
  • Instituto Butantan
  • 田邊三菱製藥
  • Nanotherapeutics Inc.
  • Protein Sciences Corporation
  • Roche Holding AG
  • Sanofi SA
  • Shanghai Institute of Biological Products Co., Ltd.
  • Shionogi & Co., Ltd.
  • Sinovac Biotech Ltd.

第5章 主要企業趨勢

第6章 全球市場概要

  • 全球流感疫苗市場概要
  • 全球流感治療藥市場概要

B部分:地區市場展望

第1章 北美

  • 北美的流感疫苗市場概要:各地區
  • 主要企業

第2章 歐洲

  • 歐洲的流感疫苗市場概要:各地區
  • 主要企業

第3章 亞太地區

  • 亞太地區的流感疫苗市場概要:各地區
  • 主要企業

第4章 中南美

  • 中南美的流感疫苗市場概要:各地區
  • 主要企業

第5章 中東、非洲

C部分:產業指南

  • 北美
  • 歐洲
  • 亞太地區
  • 其他 (ROW)

D部分:附錄

圖表清單

目錄
Product Code: PH015

The influenza virus has been implicated in infecting millions of individuals on an annual basis, with vaccination programs against seasonal influenza infections necessitating the manufacture of hundreds of million doses within a very short time period. The emergence of innovative production systems based on mammalian or insect cell cultures have resulted in surmount the hurdles associated with the egg-based production system. These industrially well-established production systems provide a faster and more flexible response to pandemic threats.

The existing range of influenza vaccines are produced in fertilized eggs, the embryo of which is infected in order that the virus can proliferate. Following a period of incubation, the virus is harvested and purified. This system of production is complicated and lacking in the event of a pandemic due to the possibility of generating low yields, not being amenable to rapid scale-up and being dependent on the availability of eggs. Global authorities have acknowledged problems associated with manufacturing vaccines based on eggs, resulting in creating a need for developing alternative vaccine production systems. The current scenario has been focusing on the development of manufacturing systems based on plants, bacteria, yeast and cell cultures.

Worldwide market for Influenza Vaccines is analyzed in both volumes in doses and value in USD for the period from 2012 through to 2022. The market for influenza therapeutics is analyzed in terms of value only at a global level. The global market for overall influenza is estimated to be US$6.1 billion in 2016 and anticipated to reach US$10.2 billion by 2022, witnessing a robust 8.5% CAGR between 2016 and 2022. Vaccines account for about 80% of the influenza market while therapeutics account for the remaining. However, therapeutics segment is projected to be the fastest growing with a CAGR of 11% during the aforementioned analysis period.

The report reviews, analyses and projects the Influenza therapeutics market at the global level while vaccines market is explored in and the regional markets including North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa.

This 128 page market research report includes 30 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. This report profiles 16 key global players and 39 major players across North America - 8; Europe - 10; Asia-Pacific - 20 and South & Central America - 1. The research also provides the listing of the companies engaged in research and development, manufacturing and supply of influenza vaccines and therapeutic. The global list of companies covers addresses, contact numbers and the website addresses of 80 companies.

Table of Contents

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

  • 1.1. Product Outline
    • 1.1.1. What is Influenza?
    • 1.1.2. Influenza Virus Types
    • 1.1.3. Influenza Types
      • 1.1.3.1. Seasonal Influenza
      • 1.1.3.2. Pandemic Influenza
      • 1.1.3.3. Zoonotic Influenza
    • 1.1.4. Treatment of Influenza
      • 1.1.4.1. Neuraminidase Inhibitors
      • 1.1.4.2. M2. Inhibitors
    • 1.1.5. Influenza Vaccine Production Technologies
      • 1.1.5.1. Egg Based Vaccine Manufacturing Technology
      • 1.1.5.2. Cell Culture Based Vaccine Manufacturing Technology
      • 1.1.5.3. Recombinant Production Technology

2. MAJOR PRODUCTS IN PIPELINE

  • 2.1. Influenza Vaccines in Pipeline
  • 2.2. Influenza Therapeutics in Pipeline

3. KEY MARKET TRENDS

  • 3.1. Development of Novel Anti-Influenza Drugs to be Guided by Research
  • 3.2. Potential to Reduce Influenza-Associated Atrial Fibrillation Shown by Flu Vaccine
  • 3.3. Designer Drugs for Combating Flu
  • 3.4. Influenza Vaccines Based on Cell Culture Gaining Traction
    • Production of Influenza Vaccine Using Mammalian Cell Culture
    • Production of Influenza Vaccine Using Insect Cell Culture
  • 3.5. Emerging Technologies for Influenza Vaccine Production
    • Virus-Like Particles Influenza Vaccine
    • Vectored Influenza Vaccine
    • Cell-Based Produced LAIV
  • 3.6. Traditional Seasonal Flu Vaccines Confront Challenge from Plant-Based Vaccines!
  • 3.7. HHS Makes Progress in Developing Innovative Drug for Treating Influenza

4. KEY GLOBAL PLAYERS

  • Abbott Laboratories
  • Astrazeneca PLC
  • Biocryst Pharmaceuticals, Inc.
  • CSL Limited
  • Daiichi Sankyo Co., Ltd.
  • Glaxosmithkline PLC
  • Hualan Biological Engineering Inc.
  • Instituto Butantan
  • Mitsubishi Tanabe Pharma Corporation
  • Nanotherapeutics Inc.
  • Protein Sciences Corporation
  • Roche Holding AG
  • Sanofi SA
  • Shanghai Institute of Biological Products Co., Ltd.
  • Shionogi & Co., Ltd.
  • Sinovac Biotech Ltd.

5. KEY BUSINESS TRENDS

  • Roche in an Alliance with Shionogi for Anti-Flu Drug S-033188
  • Unveiling of Janssen Diagnostics' New Idylla™ Respiratory IFV-RSV Panel
  • Establishment of a New Corporate Office for Seqirus in the United Kingdom
  • Seqirus' FLUAD™ (Influenza Vaccine, Adjuvanted) Approved by US FDA
  • Mexican Regulatory Authorities Approved Flublok® Influenza Vaccine for Adults 18 and Older
  • Seqirus, World's No.2 Influenza Vaccine Provider
  • Sanofi Pasteur Presented New Synthetic Vaccine COBRA at the World Vaccine Congress in Spain
  • First CLIA-Waived, Real-Time PCR Test for Influenza A and B Detection in 20 Minutes
  • Nationwide Availability of Flublok® Influenza Vaccine
  • Sinovac Supplies Seasonal Influenza Vaccine for 2015 Vaccination Campaign in Beijing
  • Daiichi Sankyo Receives License to Develop and Commercialize FluMist® Quadrivalent in Japan
  • Janssen and the Scripps Research Institute to Develop a Universal Flu Vaccine
  • Novartis Influenza Vaccine Business Acquired by CSL
  • GSK and bioCSL Amp Flu Vaccine Dose Count Shipped to the US
  • Sanofi Pasteur's Flu Vaccines Meet the Immunization Needs of People of Multiple Age Groups
  • FDA Approved Protein Sciences' Flublok® Influenza Vaccine Formulated for the 2015-16 Flu Season
  • Outperformance of Flublok® Quadrivalent Compared to Conventional Influenza Vaccine
  • bioCSL Receives Exclusive Global Rights to Commercialize RAPIVAB®
  • Flublok® Receives FDA Regulatory Exclusivity for 12 Years under the Affordable Care Act
  • Cipla Joined Forces with Serum Institute for Exclusive Sale of Nasovac-S Flu Vaccine in India
  • Zydus Cadila to Introduce 10 Shots in the Indian Vaccines Market
  • Daiichi Sankyo Partner with Chemo-Sera-Therapeutic Research Institute to Sell Kaketsuken
  • US FDA Licensed Protein Sciences' New York Production Plant for Producing Flublok®
  • Japan Vaccine Applied for the Production and Sales Approval for The Vaccine in Japan
  • Release of Serum Institute's NasoVac S Vaccine to Protect People from H1N1 Virus and Influenza A and B
  • Alere™ i Influenza A & B test, the First-Ever CLIA Waived Molecular Test to Identify and Differentiate Influenza A and B Virus within 15 Minutes
  • CDC Receives Letter from Connecticut Representatives Urging the Purchase of Protein Sciences' Flublok Vaccine
  • Protein Sciences Form Pact to Assess Possible Sources for Flublok Influenza Vaccine from Japan
  • First Ever Approval from FDA for an Intravenous Flu Drug
  • Baxter's Patented Vero Cell Technology Platform Purchased by Nanotherapeutics
  • Protein Sciences' Flublok® Influenza Vaccine Effective Against H3N2 Viruses
  • Sanofi Pasteur Received Approval for the Supplemental Biologics License Application for Fluzone Intradermal Quadrivalent Vaccine from the US FDA
  • US FDA Approval for Protein Sciences' Flublok Influenza Vaccine for People Aged 18 and Older
  • Liomont Granted with an Exclusive License to Flublok® and Panblok® Influenza Vaccines for the Mexico Market and other Latin American Nations
  • Beijing CDC Chosen Sinovac to be a Supplier of Seasonal Influenza Vaccines to the Citizens of Beijing for 2014
  • Divestiture of Abbott's Ex-US Branded Generic Drug Business
  • Janssen and Vertex Inked an Exclusive License Deal to Develop, Produce and Commercialize VX-787
  • BARDA Exercised Option Period 2 of its Deal with Protein Sciences Corporation to Develop Flublok® and Panblok®
  • FDA Grants First Time Approval for Producing Cell-Based Flu Vaccines in the US
  • Astellas Pharma Submitted Application for Marketing Approval of Recombinant Influenza HA Vaccine in Japan
  • Japanese Ministry of Health, Labour and Welfare Chosen Kitasato Daiichi Sankyo Vaccine for the Initiative of Cell Culture Vaccine Production Facility Capacity Building
  • Clinical Trial Application with CFDA Submitted by Sinovac for its Patented H7N9 Vaccine
  • Acquisition of Key Supplier to BD Diagnostics' Point-of-Care Instrument Platform by BD
  • Daiichi Sankyo's Inavir® Inhibitor Approved for Use in the Japanese Market
  • AstraZeneca Receives EC Approval for Fluenz Tetra to Treat Seasonal Influenza in People aged 2-18 Years
  • US FDA Approved GSK's H5N1 Virus Monovalent Vaccine, Adjuvanted for Adults aged 18 and Older
  • New Phase III Clinical Studies of Recombinant Seasonal Influenza HA Vaccine ASP7374 Completed Successfully
  • PHARMAC Signed Influenza Vaccine Supply Deals with Abbott and GSK
  • US FDA's Proposed New Standards for Test Performance Improvement Accepted by BD
  • Fluzone High-Dose Vaccine Evidenced Superior Immune Responses than Standard Dose Fluzone Vaccine in the Prevention of Influenza in Older Adults
  • FDA Released the First lots of Sanofi Pasteur's Fluzone® for Shipment for the 2013-2014 Season
  • Special 510(k) Clearances Granted for Quidel's Updated Package Inserts for its Rapid Diagnostic Tests for Influenza
  • Medicago to Become the Joint Venture Company of Mitsubishi Tanabe Pharma and Philip Morris Investments
  • A New Drug Application to the Ministry of Health, Labour and Welfare in Japan for the Cell Culture-Based Pandemic Influenza Vaccine Filed by Kitasato Daiichi Sankyo Vaccine
  • FDA Approved Fluzone® Quadrivalent Vaccine for use in Patients of All Age Groups
  • New Vaccine for Protection from H7N9 Influenza Virus to be Developed by Protein Sciences
  • Production of Influenza Vaccine Restarted by bioCSL for the Australian Market
  • GSK's Quadrivalent Influenza Vaccine Receives Approval from PEI in Germany and MHRA in the UK
  • Protein Sciences' Flublok® Influenza Vaccine Receives Approval from the US FDA
  • FDA Extends its Approval for Tamiflu to Treat Influenza in Infants Aged Two Weeks and Older
  • First Intramuscular Vaccine to Cover Against Four Influenza Strains Received FDA Approval
  • Protein Sciences Signs Deal with Pfizer to Broaden Vaccine Production Operations
  • Daiichi Sankyo Filed an Application for a Partial Label Modification in Japan to Produce and Market Inavir® Dry Powder Inhaler
  • Outline of Phase II and Phase III Clinical Studies for Sanofi Pasteur's Investigational QIV Displayed at IDWeek™
  • US Government Selected CSL Biotherapies for Supplying Pre-Pandemic and Pandemic Vaccine Antigens
  • Beijing CDC Chosen Sinovac for Supplying Seasonal Influenza Vaccine to Beijing Citizens
  • Restructuring of Infectious Diseases and Vaccines R&D Operations by MedImmune
  • GSK Filed Regulatory Applications for Two of its Influenza Vaccines
  • Baxter's VEPACEL Pre-pandemic Influenza Vaccine Approved by European Commission
  • FluMist Quadrivalent, the first quadrivalent influenza vaccine approved by the FDA
  • Zydus Cadila, the First Indian Pharma Firm to Release Swine Flu Vaccine

6. GLOBAL MARKET OVERVIEW

  • 6.1. Global Influenza Vaccines Market Overview
    • 6.1.1. Global Influenza Vaccines Market Overview by Geographic Region
      • 6.1.1.1. Market Analysis in Doses
      • 6.1.1.2. Market Analysis in USD
  • 6.2. Global Influenza Therapeutics Market Overview

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. NORTH AMERICA

  • 1.1. North American Influenza Vaccines Market Overview by Geographic Region
    • 1.1.1. Market Analysis in Doses
    • 1.1.2. Market Analysis in USD
  • 1.2. Major Market Players
    • Abbott Laboratories (United States)
    • BioCryst Pharmaceuticals, Inc. (United States)
    • Microbix Biosystems Inc. (Canada)
    • Nanotherapeutics Inc. (United States)
    • OPKO Health, Inc. (United States)
    • Pfizer Inc (United States)
    • Protein Sciences Corporation (United States)
    • Vivaldi Biosciences Inc. (United States)

2. EUROPE

  • 2.1. European Influenza Vaccines Market Overview by Geographic Region
    • 2.1.1. Market Analysis in Doses
    • 2.1.2. Market Analysis in USD
  • 2.2. Major Market Players
    • Astrazeneca PLC (United Kingdom)
    • MedImmune, LLC (United States)
    • Federal State Scientific-Industrial Company MICROGEN (Russia)
    • Glaxosmithkline PLC (United Kingdom)
    • Japan Vaccine Co., Ltd. (Japan)
    • NTpharma LLC (Russia)
    • OMNINVEST Vaccine Manufacturing, Researching and Trading Ltd (Hungary)
    • Roche Holding AG (Switzerland)
    • Sanofi SA (France)
    • Sanofi Pasteur MSD (France)

3. ASIA-PACIFIC

  • 3.1. Asia-Pacific Influenza Vaccines Market Overview by Geographic Region
    • 3.1.1. Market Analysis in Doses
    • 3.1.2. Market Analysis in USD
  • 3.2. Major Market Players
    • Beijing Tiantan Biological Products Co., Ltd (China)
    • BIKEN (The Research Foundation for Microbial Diseases of Osaka University) (Japan)
    • BioDiem Ltd (Australia)
    • Changchun Changsheng Life Sciences Limited (China)
    • China National Biotec Group (China)
    • CSL Limited (Australia)
    • Daiichi Sankyo Co., Ltd. (Japan)
    • Dalian Aleph Biomedical Co., Ltd (China)
    • Gamma Vaccines Pty Limited (Australia)
    • Green Cross Corporation (South Korea)
    • Hualan Biological Engineering Inc. (China)
    • Kaketsuken (The Chemo-Sero-Therapeutic Research Institute) (Japan)
    • Mitsubishi Tanabe Pharma Corporation (Japan)
    • Serum Institute of India Pvt. Ltd (India)
    • Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (China)
    • Shanghai Institute of Biological Products Co., Ltd. (China)
    • Shionogi & Co., Ltd. (Japan)
    • Sinovac Biotech Ltd. (China)
    • SK Chemicals (South Korea)
    • UMN Pharma Inc. (Japan)

4. SOUTH & CENTRAL AMERICA

  • 4.1. South & Central American Influenza Vaccines Market Overview by Geographic Region
    • 4.1.1. Market Analysis in Doses
    • 4.1.2. Market Analysis in USD
  • 4.2. Instituto Butantan (Brazil) - Major Market Player

5. MIDDLE EAST & AFRICA

PART C: GUIDE TO THE INDUSTRY

  • 1. NORTH AMERICA
  • 2. EUROPE
  • 3. ASIA-PACIFIC
  • 4. REST OF WORLD

PART D: ANNEXURE

  • 1. RESEARCH METHODOLOGY
  • 2. FEEDBACK

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVE

  • Chart 1: Global Influenza Market Overview (2012-2022) by Segment - Vaccines and Therapeutics in USD Million
  • Chart 2: Global Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million)
  • Chart 3: Global Influenza Vaccines Market Analysis (2012-2022) by Geographic Region - North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa in Million Doses
  • Chart 4: Glance at 2012, 2017 and 2022 Global Influenza Volume Market Share (%) by Geographic Region - North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa
  • Chart 5: Global Influenza Vaccines Market Analysis (2012-2022) by Geographic Region - North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa in USD Million
  • Chart 6: Glance at 2012, 2017 and 2022 Global Influenza Value Market Share (%) by Geographic Region - North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa
  • Chart 7: Global Influenza Therapeutics Market Analysis (2012-2022) by Geographic Region - United States, Europe, Japan and Rest of World in USD Million
  • Chart 8: Glance at 2012, 2017 and 2022 Global Influenza Therapeutics Value Market Share (%) by Geographic Region - United States, Europe, Japan and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

  • Chart 9: The Largest Independent Regions in Terms of Projected Growth (2016-2022) for Influenza Vaccines Market by Geographic Region - North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa

REGIONAL MARKET OVERVIEW

NORTH AMERICA

  • Chart 10: North American Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million)
  • Chart 11: North American Influenza Vaccines Market Analysis (2012-2022) by Geographic Region - United States, Canada and Mexico in Million Doses
  • Chart 12: Glance at 2012, 2017 and 2022 North American Influenza Vaccines Volume Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 13: North American Influenza Vaccines Market Analysis (2012-2022) by Geographic Region - United States, Canada and Mexico in USD Million
  • Chart 14: Glance at 2012, 2017 and 2022 North American Influenza Vaccines Value Market Share (%) by Geographic Region - United States, Canada and Mexico

EUROPE

  • Chart 15: European Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million)
  • Chart 16: European Influenza Vaccines Market Analysis (2012-2022) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in Million Doses
  • Chart 17: Glance at 2012, 2017 and 2022 European Influenza Vaccines Volume Market Share (%) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe
  • Chart 18: European Influenza Vaccines Market Analysis (2012-2022) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million
  • Chart 19: Glance at 2012, 2017 and 2022 European Influenza Vaccines Value Market Share (%) by Geographic Region - France, Germany, Italy, Spain, United Kingdom and Rest of Europe

ASIA-PACIFIC

  • Chart 20: Asia-Pacific Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million)
  • Chart 21: Asia-Pacific Influenza Vaccines Market Analysis (2012-2022) by Geographic Region - China, India, Japan, South Korea, Australia and Rest of Asia-Pacific in Million Doses
  • Chart 22: Glance at 2012, 2017 and 2022 Asia-Pacific Influenza Vaccines Volume Market Share (%) by Geographic Region - China, India, Japan, South Korea, Australia and Rest of Asia-Pacific
  • Chart 23: Asia-Pacific Influenza Vaccines Market Analysis (2012-2022) by Geographic Region - China, India, Japan, South Korea, Australia and Rest of Asia-Pacific in USD Million
  • Chart 24: Glance at 2012, 2017 and 2022 Asia-Pacific Influenza Vaccines Value Market Share (%) by Geographic Region - China, India, Japan, South Korea, Australia and Rest of Asia-Pacific

SOUTH & CENTRAL AMERICA

  • Chart 25: South & Central American Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million)
  • Chart 26: South & Central American Influenza Vaccines Market Analysis (2012-2022) by Geographic Region - Argentina, Brazil, Chile, Columbia, Venezuela and Rest of South America in Million Doses
  • Chart 27: Glance at 2012, 2017 and 2022 South & Central American Influenza Vaccines Volume Market Share (%) by Geographic Region - Argentina, Brazil, Chile, Columbia, Venezuela and Rest of South America
  • Chart 28: South & Central American Influenza Vaccines Market Analysis (2012-2022) by Geographic Region - Argentina, Brazil, Chile, Columbia, Venezuela and Rest of South America in USD Million
  • Chart 29: Glance at 2012, 2017 and 2022 South & Central American Influenza Vaccines Value Market Share (%) by Geographic Region - Argentina, Brazil, Chile, Columbia, Venezuela and Rest of South America

MIDDLE EAST & AFRICA

  • Chart 30: Middle East & Africa Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million)
Back to Top